ArticleCellular & molecular biology letters2026
EIF4A3-induced circUBAC2 promotes lung cancer progression via regulation of the Hippo signaling pathway.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCircular RNAs (circRNAs) are stable noncoding RNAs involved in cancer, yet their mechanisms in lung adenocarcinoma (LUAD) remain unclear. This study explores the oncogenic role of circUBAC2 in LUAD progression.
methodsDifferentially expressed circRNAs were screened by microarray. circUBAC2 expression/location was analyzed via quantitative real-time PCR (qRT-PCR), RNA in situ hybridization (RNA-ISH), and fluorescence in situ hybridization. Functional impacts were evaluated through wound healing, Transwell, EdU, colony formation, and xenograft models. circUBAC2 targets were identified by RNA-sequencing/proteomics, with protein interactions assessed via western blotting, immunoprecipitation, and ubiquitination assays. Molecular interactions were examined using dual luciferase, chromatin Immunoprecipitation (ChIP), and RNA pull-down.
resultscircUBAC2 was upregulated in LUAD tissues and correlated with poor prognosis. It promoted LUAD cell proliferation, migration, and invasion in vitro, as well as tumor growth/metastasis in vivo. Mechanistically, circUBAC2 competitively bound 14-3-3 to release YAP for nuclear translocation while scaffolding OTUB1–YAP interactions to enhance YAP deubiquitination and stabilization, collectively activating TEAD-mediated oncogenic transcription. EIF4A3 facilitated circUBAC2 biogenesis by binding flanking intronic regions.
conclusionscircUBAC2 drives LUAD progression via YAP signaling, positioning it as a therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.